Orchestra BioMed Holdings (OBIO) Net Income Growth (1y) (2022 - 2026)

Orchestra BioMed Holdings (OBIO) Net Income Growth (1y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (1y) (Qtr)
1 Oculis Holding AG 67,132.22 Bn 67,131.94 Bn - -0.46%
2 Nanobiotix 1,910.87 Bn 1,910.81 Bn - -
3 Akari Therapeutics 989.71 Bn 989.71 Bn - -
4 BeOne Medicines 471.60 Bn 466.80 Bn 1.35 Bn 17,802.13%
5 Vertex Pharmaceuticals 121.71 Bn 114.46 Bn 2.59 Bn 59.59%
6 Regeneron Pharmaceuticals 69.83 Bn 61.07 Bn 3.31 Bn -10.08%
7 Belite Bio 62.74 Bn 62.74 Bn - -
8 Argenx Se 55.83 Bn 50.65 Bn 1.41 Bn 63.48%
9 Alnylam Pharmaceuticals 37.33 Bn 34.32 Bn 959.66 Mn 1,228.66%
10 Orchestra BioMed Holdings 239.91 Mn 145.51 Mn 78,000.00 -27.72%

Historic Data

Download Data
DateValue
Mar 31, 2026 -27.72%
Dec 31, 2025 139.71%
Sep 30, 2025 -16.55%
Jun 30, 2025 14.37%
Mar 31, 2025 -22.69%
Dec 31, 2024 -31.95%
Sep 30, 2024 19.97%
Jun 30, 2024 -48.53%
Mar 31, 2024 -32.80%
Dec 31, 2023 -20.09%
Sep 30, 2023 -110.63%
Jun 30, 2023 -114.90%
Mar 31, 2023 -121.77%
Dec 31, 2022 -8,223.98%
Sep 30, 2022 -8,300.50%
Jun 30, 2022 -6,146.93%
Mar 31, 2022 -3,678.85%